---
canonical_name: Elamipretide
alternate_names: SS-31, Bendavia, MTP-131, Forzinity
canonical_topic: Elamipretide for Health & Longevity
short_topic_lc: elamipretide
creation_date: 2026-0830-1204
creator_ai_fullname: Grok 4.5
---

# Elamipretide for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/30/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5

**Also known as:** SS-31, Bendavia, MTP-131, Forzinity

<!-- Motivation written last, after all other sections, so it reflects the full scope of the review. -->
  
## Motivation

Elamipretide is a laboratory-made chain of four amino acids that was designed to enter mitochondria, the energy-producing parts of cells, and stabilize their inner membranes.  
Interest among people focused on health and longevity comes from the idea that mitochondrial decline contributes to weaker muscle, tiredness, and less resilient organs with age, so a compound that restores mitochondrial structure might, in principle, support those tissues.

The peptide was discovered in academic chemistry work, advanced by a biotechnology company through many disease trials, and in 2025 received U.S. approval to improve muscle strength in Barth syndrome, a rare inherited mitochondrial condition that mainly affects males.  
That approval does not settle whether the same daily injection helps generally healthy adults.  
The same molecule has also been studied in mitochondrial muscle disease, heart failure, and aging muscle.

This review examines the human evidence for and against elamipretide as a health and longevity intervention: how it is thought to work, what benefits and harms have been measured, how it is used, and what remaining uncertainties matter for risk-aware adults considering peptides aimed at cellular energy production.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
  
## Recommended Reading

High-level overviews of elamipretide, its mitochondrial targeting, and the gap between Barth syndrome approval and longevity claims.

<!-- Search 2026-08-30: web search "elamipretide OR SS-31" plus Peter Attia, Rhonda Patrick, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io. On-site: peterattiamd.com AMA #83 (substantial SS-31 case study); foundmyfitness.com search elamipretide = no results; hubermanlab.com search = no dedicated items; chriskresser.com search elamipretide and SS-31 = no results; lifeextension.com search did not return a dedicated article; lifespan.io search returned a dedicated mouse-frailty article. PubMed narrative reviews Tung 2025 and Sabbah 2025, plus Szeto 2014 discoverer review. Excluded systematic reviews, Wikipedia, forums, and mainstream news. -->

- [#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field](https://peterattiamd.com/ama83/) - Peter Attia

  Places SS-31 in a peptide-evaluation framework covering Barth syndrome (a rare inherited mitochondrial muscle and heart disease), unlicensed research-chemical use, and why longevity claims remain speculative.

- [Elamipretide, a Potential New Drug, Reduces Frailty in Mice](https://lifespan.io/elamipretide-a-potential-new-drug-reduces-frailty-in-mice/) - Josh Conway

  Summarizes the 2025 *Aging Cell* mouse work: frailty and heart function improved, while epigenetic and transcriptomic age markers barely moved.

- [Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential](https://pubmed.ncbi.nlm.nih.gov/39940712/) - Tung et al., 2025

  Narrative of chemistry, cardiolipin (the inner-mitochondrial-membrane lipid this peptide binds), animal models, and the main human programs.

- [Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects](https://pubmed.ncbi.nlm.nih.gov/40294492/) - Sabbah et al., 2025

  Updates the cardiolipin-binding account and reviews Barth syndrome, primary mitochondrial myopathy, and macular-degeneration trial results.

- [First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics](https://pubmed.ncbi.nlm.nih.gov/24117165/) - Szeto, 2014

  Discoverer's review of how SS-31 was designed, why cardiolipin was chosen as a target, and how animal bioenergetic effects were first framed.

No dedicated elamipretide content was found from Rhonda Patrick, Andrew Huberman, Chris Kresser, or Life Extension Magazine.
  
## Grokipedia

<!-- Direct browser search of grokipedia.com for "elamipretide" on 2026-08-30 returned a dedicated article at /page/Elamipretide (also listed as /page/elamipretide and a related SS-31 page). Primary dedicated page used. -->

- [Elamipretide](https://grokipedia.com/page/Elamipretide)

  Encyclopedia-style overview of chemistry, Barth syndrome approval, failed and ongoing trials, and the remaining investigational uses.
  
## Examine

<!-- Browser navigation to examine.com/search/?q=elamipretide on 2026-08-30 hit a Vercel Security Checkpoint; d-fetch returned HTTP 403. Independent web search site:examine.com elamipretide OR SS-31 returned no Examine.com pages. No dedicated Examine article found. -->

No Examine.com article for elamipretide was found. Examine.com does not typically cover prescription medications.
  
## ConsumerLab

<!-- Direct fetch of consumerlab.com/search/?q=elamipretide on 2026-08-30 returned no dedicated product review, clinical update, or recall for elamipretide; the only listed "product review" was an unrelated NAD booster review. -->

No ConsumerLab article for elamipretide was found. ConsumerLab does not typically cover prescription medications.
  
## Systematic Reviews

PubMed records that pool mitochondrial-targeted agents, including elamipretide, for metabolic, vascular, or heart-failure outcomes.

<!-- PubMed search 2026-08-30: elamipretide OR "SS-31" OR Bendavia OR MTP-131 AND (systematic review OR meta-analysis). Hits: Mason 2022 (mito-targeted antioxidants, includes elamipretide); Mohammed 2026 (mitochondrial-targeted agents in heart failure); others were scoping reviews, wound-healing SRs with only passing mention, or unrelated. No systematic review dedicated solely to elamipretide, and none of injection-site reactions or hypersensitivity. -->

- [Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/35165982/) - Mason et al., 2022

  Pools elamipretide with MitoQ and MitoTEMPO; only brachial flow-mediated dilation improved, with very-low certainty.

- [Therapeutic targeting of mitochondrial dysfunction in heart failure: a systematic review & meta-analysis of clinical outcomes](https://pubmed.ncbi.nlm.nih.gov/42440741/) - Mohammed et al., 2026

  Pools many mitochondrial-targeted agents in heart failure; class-level gains are not elamipretide-specific, and elamipretide's own heart-failure trial was negative.

No systematic review of elamipretide's principal risk (injection-site reactions or hypersensitivity) was found.
  
## Mechanism of Action

Elamipretide is a synthetic aromatic-cationic tetrapeptide (D-Arg-2,6-dimethylTyr-Lys-Phe-NH2) that concentrates more than 1,000-fold at the inner mitochondrial membrane independently of membrane potential.  
The long-standing account is that it binds cardiolipin, the signature phospholipid of that membrane, stabilizing cristae folds, supporting electron-transport supercomplexes, lowering electron leak, and raising adenosine triphosphate (ATP, the cell's energy currency) output in stressed mitochondria.  
Biophysical work shows the peptide also partitions into the membrane interface and alters surface electrostatics, changing how ions and proteins sit at the bilayer.  
A 2024 [clustered regularly interspaced short palindromic repeats (CRISPR, a gene-editing screen) study](https://pubmed.ncbi.nlm.nih.gov/38530359/) identified phospholipid scramblase 3 (PLSCR3, an inner-membrane lipid-moving protein) as required for SS-31's mitoprotective effect in kidney-injury models, so cardiolipin binding and PLSCR3 engagement are competing, possibly complementary, explanations.

Pharmacologically, about 92% of a subcutaneous dose reaches the bloodstream (bioavailability), peak plasma levels occur at 0.5–1 hour, plasma protein binding is about 39%, and the peptide spreads through body water (volume of distribution about 0.5 L/kg).  
The plasma half-life is about 3–4 hours with little accumulation on daily dosing.  
The peptide is not metabolized by cytochrome P450 enzymes (CYP, liver drug-processing proteins); it is clipped at the C-terminus to inactive M1 and M2 fragments and cleared by the kidney.  
It does not inhibit major CYP enzymes or most transporters, but it inhibits MATE1 (multidrug and toxin extrusion transporter 1, a kidney and liver pump that helps clear drugs such as metformin).
  
## Historical Context & Evolution

Elamipretide began as SS-31, a Szeto–Schiller peptide made when Hazel Szeto and Peter Schiller were designing cell-permeable opioid-related peptides and noticed unexpected mitochondrial uptake.  
Szeto later described the finding as serendipitous: analogs that barely bound opioid receptors still concentrated on the inner mitochondrial membrane and appeared to protect bioenergetics in injury models.  
Stealth BioTherapeutics, the manufacturer that later commercialized the drug and funded the late-stage human trials (a direct financial interest in adoption), licensed the chemistry, renamed it MTP-131 and Bendavia, and ran a broad program aimed at ischemia–reperfusion (injury when blood returns after a blockage), heart failure, kidney injury, mitochondrial myopathy (muscle weakness from failed cellular energy production), Barth syndrome, and retinal disease.

Human development produced mixed results.  
[EMBRACE-STEMI](https://pubmed.ncbi.nlm.nih.gov/26586786/) did not shrink infarct size.  
[PROGRESS-HF](https://pubmed.ncbi.nlm.nih.gov/32068002/) did not improve left-ventricular volumes in heart failure with reduced ejection fraction (HFrEF, a weak-pump heart-failure phenotype).  
[MMPOWER-3](https://pubmed.ncbi.nlm.nih.gov/37268435/), a 218-person phase 3 trial in primary mitochondrial myopathy, missed both primary functional endpoints.  
[TAZPOWER](https://pubmed.ncbi.nlm.nih.gov/33077895/), a 12-person Barth syndrome crossover, also missed its randomized primary endpoints; the subsequent [open-label extension](https://pubmed.ncbi.nlm.nih.gov/38602181/) reported larger walk-distance and strength gains.  
U.S. regulators granted [accelerated approval](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome) (authorization on an intermediate strength measure while a confirmatory trial continues) in September 2025 as Forzinity for Barth syndrome in people weighing at least 30 kg, even though that same program's randomized comparison did not meet its primary endpoints.  
That history is why longevity-oriented use sits on a mechanism-first argument rather than a completed functional-outcome program in typical adults.
  
## Expected Benefits

<!-- Benefit-profile search 2026-08-30: PubMed title search elamipretide/SS-31/Bendavia/MTP-131; TAZPOWER RCT and 168-week OLE; MMPOWER, MMPOWER-2, MMPOWER-3 and nDNA post-hoc; ReCLAIM-2; Karanjia 2024 topical LHON RCT; Roshanravan older-adult ATP trial; PROGRESS-HF; EMBRACE-STEMI; Mason 2022 and Mohammed 2026 SRs; Aging Cell mouse frailty paper; Attia AMA #83; FDA snapshot and Forzinity label via DailyMed. Major claimed benefits: Barth muscle strength/walk distance, PMM exercise capacity, dry AMD photoreceptor preservation, LHON visual acuity, older-adult mitochondrial ATP, heart-failure remodeling, infarct-size reduction, general energy/performance, mouse aging muscle/heart. Negative or failed programs (STEMI, HFrEF, MMPOWER-3 primary, LHON BCVA primary) are treated as absent or conflicted benefits, not omitted. -->

### High 🟩 🟩 🟩

No benefit reaches High: replicated human clinical endpoints outside a single ultra-rare disease program are lacking, and that program's randomized phase did not meet its primary endpoints.

### Medium 🟩 🟩

No benefit reaches Medium: no single consistent human clinical-endpoint trial supports a longevity-relevant outcome; Barth function data conflict across the randomized and open-label phases.

### Low 🟩

#### Knee Extensor Strength in Barth Syndrome ⚠️ Conflicted

40 mg daily subcutaneous elamipretide is approved for Barth syndrome knee-extensor strength.  
The 12-person [TAZPOWER](https://pubmed.ncbi.nlm.nih.gov/33077895/) crossover did not show a significant randomized strength change.  
The [168-week open-label extension](https://pubmed.ncbi.nlm.nih.gov/38602181/) reported strength gains.  
Net reading: open-label follow-on strength gains are the approval basis, but the controlled phase was negative.

**Magnitude:** Knee-extensor strength rose 37.9–60.3 newtons versus open-label baseline across extension visits (P < 0.05, the chance of this result if there were no real effect) in 8 completers; the randomized 12-week comparison was not significant.

#### Photoreceptor Ellipsoid-Zone Preservation in Dry Age-Related Macular Degeneration

[ReCLAIM-2](https://pubmed.ncbi.nlm.nih.gov/39605874/) (n = 176) missed primary vision and atrophy endpoints after 48 weeks of 40 mg daily.  
Ellipsoid-zone (EZ, the photoreceptor band on retinal imaging) loss slowed, with more treated eyes gaining ≥10 low-luminance letters.  
This is one trial with nominal secondary imaging results.

**Magnitude:** 43% less progression of complete EZ attenuation versus placebo at week 48 (nominal P = 0.0034, not adjusted for multiple tests); 14.6% versus 2.1% gained ≥10 low-luminance letters.

#### Visual Acuity in Leber Hereditary Optic Neuropathy ⚠️ Conflicted

A 12-person [topical-drop trial](https://pubmed.ncbi.nlm.nih.gov/37923251/) in Leber hereditary optic neuropathy (LHON, a mitochondrial optic-nerve disease) missed its primary visual-acuity endpoint versus vehicle.  
Open-label and post-hoc (analyzed after the data were in, not as a pre-planned test) visual-field signals appeared.  
Net reading: the controlled phase was negative; remaining signals are hypothesis-generating.

**Magnitude:** Best-corrected visual acuity was not significantly different from vehicle at any time point; 6 of 12 participants met a post-hoc clinically relevant-benefit criterion.

#### Exercise Capacity in Primary Mitochondrial Myopathy ⚠️ Conflicted

A [4-week crossover](https://pubmed.ncbi.nlm.nih.gov/32096613/) reported walk and fatigue signals the 218-person [MMPOWER-3](https://pubmed.ncbi.nlm.nih.gov/37268435/) trial did not confirm.  
A [post-hoc nuclear-DNA (nDNA) subgroup](https://pubmed.ncbi.nlm.nih.gov/39574155/) suggested walk gains the mitochondrial-DNA (mtDNA) majority lacked.  
Net reading: the large trial was negative; the nDNA signal is hypothesis-generating.

**Magnitude:** MMPOWER-3 6-minute walk test (6MWT, timed walking capacity) difference −3.2 m versus placebo (95% confidence interval (CI, the range of values reasonably consistent with the data) −18.7 to 12.3; P = 0.69); MMPOWER-2 6MWT +19.8 m (P = 0.0833) over 4 weeks.

### Speculative 🟨

#### Age-Related Cardiac and Skeletal Muscle Function

[Eight-week treatment in old mice](https://pubmed.ncbi.nlm.nih.gov/40080911/) improved frailty, heart filling, and muscle force without shifting epigenetic age.  
No equivalent controlled human aging trial has finished; a 4-week older-adult pilot is recruiting.

#### Muscle ATP Capacity After a Single Infusion in Older Adults

A randomized [single-infusion study](https://pubmed.ncbi.nlm.nih.gov/34264994/) in older adults raised muscle ATP-generating capacity without improving fatigue resistance.  
The signal was gone by day 7.

#### General Energy, Recovery, and Performance in Healthy Adults

Clinic and unlicensed-peptide claims that SS-31 raises everyday energy or training capacity rest on mechanism and anecdote.  
Controlled human outcome data in people without mitochondrial disease are essentially absent.
  
## Benefit-Modifying Factors

- **TAZ and cardiolipin remodeling:** Barth syndrome (pathogenic variants in tafazzin/TAZ, the gene that remodels cardiolipin) is the only population with an approved strength claim; that genotype is not a longevity-screening target.

- **nDNA versus mtDNA myopathy:** MMPOWER-3's negative overall result and nDNA post-hoc signal imply variants in the nuclear genes that copy mitochondrial DNA (the replisome) may respond differently from mtDNA genotypes.

- **Baseline mitochondrial capacity:** The older-adult ATP trial enrolled people with poorly functioning mitochondria; young or already-efficient muscle showed little change in animal work.

- **Sex:** Barth trials were almost entirely male. MMPOWER-3 was 64% women. Mouse muscle-force effects have been sex-dependent; human longevity-use sex differences are unmeasured.

- **Age:** Barth studies did not enroll people ≥65 years. The ATP trial enrolled older adults; the recruiting SHAPE pilot targets ages 65–80 with lower aerobic capacity.

- **Pre-existing mitochondrial or retinal disease:** Functional signals cluster in Barth syndrome, selected nDNA myopathy, and dry age-related macular degeneration (AMD) imaging—not in unselected heart-failure or STEMI (ST-elevation myocardial infarction, a complete coronary occlusion) populations.
  
## Potential Risks & Side Effects

<!-- Risk-profile search 2026-08-30: Drugs.com Forzinity patient page and elamipretide professional monograph; FDA Drug Trials Snapshot; TAZPOWER RCT/OLE; MMPOWER-3; ReCLAIM-2; EMBRACE-STEMI; trial exclusion criteria for eosinophilia (NCT07531251, NCT06373731, NCT05162768); PubMed AE mentions. Principal risks: injection-site reactions, hypersensitivity, eosinophilia, benzyl-alcohol neonatal warning, renal exposure increase. -->

### High 🟥 🟥 🟥

#### Injection-Site Reactions

Local erythema (redness), pain, induration (hardening), pruritus (itching), bruising, and urticaria (hives) are the dominant adverse events across Barth, myopathy, and retina programs.  
They are usually mild to moderate and managed with oral antihistamines or topical corticosteroids, but they drive discontinuations and make daily self-injection a practical barrier.  
This is a replicated human clinical adverse-event finding, not a biomarker shift.

**Magnitude:** Any local administration reaction occurred in 100% of Forzinity-treated [TAZPOWER](https://pubmed.ncbi.nlm.nih.gov/33077895/) participants (erythema 100%, pain 75%, induration 67%, pruritus 67%); [MMPOWER-2](https://pubmed.ncbi.nlm.nih.gov/32096613/) reported injection-site reactions in 80%.

### Medium 🟥 🟥

#### Hypersensitivity

The [Forzinity label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75) and the [first-approval review](https://pubmed.ncbi.nlm.nih.gov/41335372/) warn that serious allergic reactions requiring emergency treatment have occurred, with rash, skin lesions, or cough appearing minutes to months after starting.  
Serious hypersensitivity is an absolute contraindication to rechallenge.  
Mild skin reactions may still be managed with antihistamines and topical corticosteroids.

**Magnitude:** Incidence is not reported as a pooled trial percentage; labeled serious reactions have occurred, and the product is contraindicated after a serious event.

### Low 🟥

#### Eosinophil Increases

Repeat-dose programs treat eosinophil (allergy-type white blood cell) rises as a watch item, including exclusions for counts >1,000 cells/µL.  
The [MMPOWER-3](https://pubmed.ncbi.nlm.nih.gov/37268435/) safety dataset flags this pattern, but published papers give no symptomatic disease rate.

**Magnitude:** Absolute eosinophil counts rose by a mean of about 0.5–0.6 × 10³/µL, peaking near day 90, in programs lasting 30 days or longer; the rise was not linked to clinical eosinophilic disease.

### Speculative 🟨

#### Blunting of Adaptive Mitochondrial Oxidant Signaling

If the peptide lowers electron leak in healthy mitochondria, it could blunt oxidant signals used in training.  
This remains mechanistic only, without outcome data in trained adults.
  
## Risk-Modifying Factors

- **Prior peptide or excipient allergy:** Serious hypersensitivity to elamipretide or Forzinity excipients (including benzyl alcohol) is an absolute contraindication.

- **Kidney filtration:** Severe impairment (eGFR, estimated glomerular filtration rate, a kidney-filtration estimate, <30 mL/min, not on dialysis) raises exposure about 125%; the labeled dose is 20 mg daily.

- **Sex:** Barth syndrome is X-linked and almost exclusively male; injection-site and allergy rates have not been shown to differ by sex in mixed trials.

- **Eosinophilic disease:** Systemic eosinophilic illness and high baseline eosinophils were exclusion criteria in late trials.

- **Age and neonates:** Barth trials did not enroll ages ≥65. The product is not approved in neonates; benzyl alcohol has caused gasping syndrome (fatal newborn acidosis with struggling breaths) after intravenous use in preterms.

- **Injection-site skin quality:** Tender, scarred, or inflamed skin increases local reactions; daily site rotation is the main modifier.
  
## Key Interactions & Contraindications

- **MATE1 substrates (metformin):** Caution. Elamipretide inhibits MATE1 (IC50 3.53 µM, the concentration that halves transporter activity) near peak levels, which can raise metformin exposure; glucose and dose need watching.

- **Aspirin, clopidogrel, unfractionated heparin:** No meaningful pharmacokinetic or antiplatelet/anticoagulant interaction in dedicated infusion studies; no extra bleeding signal from those probes.

- **CYP-metabolized drugs (simvastatin, omeprazole, midazolam):** No interaction expected. Elamipretide does not inhibit or induce major CYP enzymes and is not hepatically metabolized.

- **Mitochondrial supplements (coenzyme Q10, L-carnitine, creatine, MitoQ):** Caution. Potential additive bioenergetic claims, untested as combinations. The recruiting older-adult SHAPE trial asks participants to stop these during dosing.

- **Other mitochondrial peptides (MOTS-c) and oxidant-cycling agents (methylene blue):** Theoretical stacking on the same organelle; no controlled human combination data. Monitor for redundant injection burden and uninterpretable fatigue changes.

- **Oral antihistamines (cetirizine, diphenhydramine):** Not a harmful pharmacokinetic interaction. They are used to treat injection-site reactions; sedation from older antihistamines can add daytime sleepiness.

**Populations who should avoid Elamipretide:**

- **Serious hypersensitivity:** Absolute contraindication. Rechallenge after a severe whole-body allergic reaction is not part of labeled use.

- **Neonates and preterm infants:** Not a labeled population. Benzyl alcohol in the vial carries a gasping-syndrome warning after intravenous exposure in low-birth-weight neonates.

- **Severe renal impairment on dialysis:** Dose not established; labeled 20 mg daily applies only if eGFR <30 mL/min and the person is not on dialysis.
  
## Risk Mitigation Strategies

- **Site rotation and skin care:** Abdomen (≥2 inches from the navel) or outer thigh, new site daily, skip tender or scarred skin—reduces injection-site reactions.

- **Antihistamines and topical corticosteroids:** Labeled options for mild-to-moderate local erythema, itch, or urticaria, lowering discontinuation from injection-site reactions.

- **Hypersensitivity stop rule:** Permanent discontinuation and emergency treatment (epinephrine, antihistamines, corticosteroids) if systemic allergy appears.

- **Renal dose cut:** 20 mg daily when adult eGFR is <30 mL/min and the person is not on dialysis, limiting accumulation.

- **Eosinophil screening:** Baseline and follow-up complete blood count with differential, holding use if a systemic eosinophilic illness emerges.

- **Missed-dose rule:** Skip a missed injection and take the next at the usual time; no double dose, limiting peak-related reactions.
  
## Therapeutic Protocol

- **Approved Barth regimen (Forzinity):** 40 mg subcutaneously once daily at the same time each day in people ≥30 kg, from the TAZPOWER program and the U.S. label.

- **Longevity-clinic cycling:** Peter Attia's peptide AMA covers unlicensed SS-31 use; some clinics use multi-week subcutaneous courses rather than daily labeled therapy, a schedule not trial-validated for longevity.

- **Time of day:** Label specifies a consistent clock time, not a morning versus evening pharmacologic window. Peak plasma levels occur 0.5–1 hour after injection.

- **Half-life and splitting:** Plasma half-life is about 3–4 hours, yet the labeled schedule is once daily because membrane binding, not plasma levels, is the intended action. Split dosing is not in the label.

- **Genetics:** No CYP-based dose algorithm. TAZ confirms Barth eligibility; nDNA versus mtDNA myopathy may change response but does not set a labeled dose.

- **Sex:** No sex-specific dose. Barth dosing data are almost entirely male.

- **Age:** No geriatric dose adjustment. Pediatric use is labeled only at ≥30 kg.

- **Baseline energetics:** Older-adult research selected low mitochondrial function; people with already-high aerobic capacity have no protocol-level dose change.

- **Kidney disease:** 20 mg daily if adult eGFR <30 mL/min off dialysis; mild-to-moderate impairment needs no reduction.

- **Hepatic disease:** No adjustment; there is no hepatic metabolism.
  
## Discontinuation & Cycling

- **Duration:** Barth use is framed as ongoing disease-modifying therapy, not a short course. Longevity use has no evidence-based stop date.

- **Withdrawal:** No recognized withdrawal syndrome or rebound mitochondrial crash in trial reports after stopping.

- **Taper:** None specified. Plasma clearance is rapid; a missed-dose rule already skips rather than doubles.

- **Cycling:** Clinic protocols sometimes use 4–8 week on-cycles; no trial shows that cycling preserves efficacy or reduces injection-site reactions versus daily use.

- **Rechallenge after allergy:** Labeled as contraindicated after a serious hypersensitivity reaction.
  
## Sourcing and Quality

- **Approved product:** Forzinity is an 80 mg/mL multi-dose vial (280 mg/3.5 mL) of elamipretide hydrochloride with benzyl alcohol, distributed through specialty pharmacy (AnovoRx / manufacturer access programs), not retail supplement channels.

- **Identity:** Unlicensed "SS-31" lyophilized research vials are not Forzinity. After U.S. approval, compounding copies of a commercially available drug is restricted.

- **Testing:** Research-chemical lots vary in peptide content, salt form, and sterility. Third-party identity and endotoxin testing does not convert them into a licensed drug.

- **Storage:** Refrigerate unopened vials at 2–8 °C; do not freeze. After first puncture, refrigerate or keep at 20–25 °C and discard at 8 days.

- **Cost:** List price has been reported near $800,000 per year (~$15,000 per vial), so access is a dominant practical constraint.
  
## Practical Considerations

- **Time to effect:** Older-adult ATPmax (peak muscle ATP-generating capacity) rose during a 2-hour infusion and was gone by day 7. Barth walk-distance gains accumulated over months of open-label use, not days.

- **Common pitfalls:** Treating unlicensed SS-31 as equivalent to Forzinity; expecting energy or performance gains from a drug that failed larger functional trials; skipping site rotation; doubling a missed dose.

- **Regulatory status:** U.S. accelerated approval is limited to Barth syndrome at ≥30 kg. Other uses, including longevity and dry AMD, are off-label or investigational.

- **Cost and access:** Exceptionally expensive, specialty-pharmacy only, and not a consumer supplement. Daily subcutaneous injection plus refrigeration is a demanding daily-injection routine.
  
## Interaction with Foundational Habits

- **Sleep:** No direct hypnotic or alerting effect is described. Injection-site pain or antihistamines used for local reactions can disturb sleep indirectly; morning injection may limit nocturnal discomfort.

- **Nutrition:** None for food timing or typical diet patterns (clearance is renal, not CYP-based, so grapefruit is irrelevant). Indirect caution with metformin via MATE1 inhibition, so glucose still needs watching.

- **Exercise:** Direction theoretically potentiating in energy-limited muscle, but MMPOWER-3 and PROGRESS-HF did not show training-like functional gains. The older-adult ATP rise did not improve fatigue resistance; timed training studies are lacking.

- **Stress management:** None for cortisol or autonomic tone. Daily self-injection is an added logistical burden for people using it outside a disease indication.
  
## Monitoring Protocol & Defining Success

Before the first injection, a baseline set of labs and a function snapshot makes later change interpretable: kidney filtration, a complete blood count with eosinophils, and, if the goal is stamina, a timed walk or knee-strength measure plus a brief symptom diary.  
Because the peptide is cleared by the kidney and late trials excluded high eosinophil counts, those two lab domains are the safety core.  
Repeat labs at about 4 weeks, again at 12 weeks, then every 3–6 months while injections continue.  
Injection-site checks at those visits look for spreading rash, hardness, or delayed allergic signs, which have appeared from minutes to months after starting.  
Functional re-testing on the same cadence shows whether walk distance, strength, or self-rated fatigue actually moved, rather than assuming that a mitochondrial mechanism equals a noticeable gain.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --------- | ------------------------ | --------------- | ------------- |
| eGFR (CKD-EPI) | ≥90 mL/min/1.73 m²; dose-cut <30 | Exposure and dose | CKD-EPI is the Chronic Kidney Disease Epidemiology Collaboration equation. Conventional chronic-kidney-disease threshold is <60; labeled 20 mg dose is for adult eGFR <30 off dialysis. Not fasting-dependent. |
| Eosinophil count | Track versus personal baseline; hold if symptomatic eosinophilic disease or >1,000 cells/µL | Allergy-type inflammation | Conventional reference often 0–500 cells/µL. Pair with CBC (complete blood count). No time-of-day requirement. |
| CBC with differential | Individual baseline; watch hemoglobin and white-cell pattern | Systemic reaction screen | Pair with eosinophils. Injection-site infection is uncommon but visible here if systemic. |
| 6MWT or knee extensor strength | Change from the individual's own baseline; no established longevity target | Function that trials actually measured | Repeat at 4 and 12 weeks. Same course, same footwear, same time of day. |
| Symptom fatigue score | Change from diary baseline | Subjective stamina | Daily or weekly ordinal score. Unvalidated for healthy users; still the patient-reported domain trials used. |

- Energy stability across the day, not a brief post-injection lift
- Injection-site comfort and absence of spreading rash or hives
- Training recovery and walk or climb tolerance versus the pre-start diary
- Sleep quality if antihistamines or site pain are in use

Success, for a longevity-oriented user, is a durable functional change (walk, strength, or fatigue) without escalating local or systemic reactions—not a laboratory energy-capacity number alone.
  
## Emerging Research

- **Confirmatory Barth trial:** [4TAZPower (NCT07531251)](https://clinicaltrials.gov/study/NCT07531251) is a recruiting 72-week randomized, placebo-controlled phase 3b/4 study (n = 48) meant to verify Forzinity's clinical benefit after accelerated approval.

- **Aging function pilot:** [SHAPE (NCT07275424)](https://clinicaltrials.gov/study/NCT07275424) is a recruiting 4-week open-label phase 2a study of daily subcutaneous elamipretide in 30 adults aged 65–80 with lower aerobic capacity, measuring safety, inflammation, walk distance, strength, and cognition.

- **Dry age-related macular degeneration (AMD) phase 3:** [ReNEW (NCT06373731)](https://clinicaltrials.gov/study/NCT06373731) is an active, fully enrolled 96-week trial (n = 313) using macular photoreceptor-loss rate as the primary endpoint after ReCLAIM-2 missed its original primary outcomes.

- **Nuclear-DNA myopathy:** [NuPower (NCT05162768)](https://clinicaltrials.gov/study/NCT05162768) completed 48-week 60 mg versus placebo in nDNA primary mitochondrial disease (n = 102) without posted results; a positive readout would revive the nDNA subgroup hypothesis, a negative one would weaken it.

- **Mouse aging without epigenetic rejuvenation:** [Mitchell et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40080911/) found better late-life cardiac and muscle function in mice without a shift in tissue epigenetic or transcriptomic age—supporting function-without-reprogramming, or showing that frailty reversal can bypass clock change.

- **PLSCR3 as required target:** [Silvaroli et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38530359/) found SS-31's kidney protection collapsed without phospholipid scramblase 3, a competing mechanism that could limit who responds if human variants matter.
  
## Conclusion

Elamipretide is a four-amino-acid injection that goes to mitochondria and is sold to improve muscle strength in Barth syndrome, a rare inherited energy-failure condition.  
For health- and longevity-oriented adults without that diagnosis, the human record is thin and mixed.  
The only approved use rests on small follow-on strength data collected in Barth syndrome after everyone knew they were receiving the drug; a randomized portion of that same program did not show a clear benefit, and several larger trials in inherited muscle energy disease, heart failure, and heart-attack injury did not meet their main everyday-function or organ-damage goals.  
A single-dose study in older muscle found a short-lived rise in the muscle's ability to make energy without a matching gain in fatigue resistance.  
The most consistent human finding is local injection-site irritation, often in most people who take the drug, with uncommon but documented allergic reactions.  
Almost all of the late-stage trials were funded by the manufacturer, Stealth BioTherapeutics, which has a direct financial interest in adoption.  
Research vials labeled as the same peptide are not the approved product and have not been shown to match its identity or purity.  
Daily injections, refrigeration, and a list price on the order of hundreds of thousands of dollars per year make this a demanding intervention whose longevity case remains an argument about how it is thought to work rather than a completed case from trials that measured everyday function in people using it for optimization.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**